Twitxy Saved

KOL Pulse AI

Verified account This account is verified. Learn more

@KolPulseAI

Instant insights from oncology’s top voices. Download the free Chrome Extension that tracks trials, sentiment & influence on X.
Savannah, GA kolpulse.com Joined August 2023
4.8K Following 1.2K Followers 16K Posts

Latest posts 5

Pinned post

KOL Pulse AI Verified account @KolPulseAI
Quick takes on the Social Signals from #ASCO26.
🧬 RASolute-302: @marklewismd 's tweet regarding the standing ovation for RASolute-302 really made that trial stand out. The momentum here was massive, fueled by high expectations from the @RevMedicines PR, #AACR26 presentations,and the high-profile Ben Sasse interviews.

⚔️ PROTEUS: One of the more interesting trials from a social media perspective, as the radiation oncology community on X was highly critical of the trial's surgical paradigm.

🔄 CROWN: Felt a bit like an incredible replay of the Plenary from years ago—steady, practice-confirming data.

🎬 HARMONi-6: Perhaps the most compelling narrative twist. The discussant, Dr. Julie Brahmer, masterfully set up the Plenary audience using The Devil Wears Prada as a research metaphor. It begs the question: Is VEGF back?

🚀 LIBRETTO-432: A massive surprise for many attendees. Lung cancer specialists were thrilled about @LillyOncMed selpercatinib in the adjuvant setting for RET-positive NSCLC. The core takeaway from @christine_lovly presentation was loud and clear: "This is why we test."

🔬 OPTIMA: Really got the breast cancer community excited about using @Veracyte 's test to safely reduce the chemotherapy burden for many of their patients.

📦 WU-KONG28: Had such an interesting vibe. Great data from @Dizal_Global , but it leaves the KOLs asking the same commercial question: Why isn't this readily available to patients in the US yet?

Follow the #ASCO26 Pre and Post highlights here: kolpulse.com/kol-pulse-asco…
kolpulse.com ASCO 2026 KOL Intelligence: Top Voices, Themes & Trial Buzz by Tumor Type | KOL Pulse The ASCO 2026 oncology KOL conversation, decoded: top physician voices, practice-changing trial readouts, and sentiment across lung, breast, GI & GU. See who is shaping the discussion — and get the...
0 replies 5 reposts 9 likes 3.2K views View on X
KOL Pulse AI Verified account @KolPulseAI
ERAS-0015, a pan-RAS molecular glue, at #ENASymp26: confirmed ORR 44.0% at 32 mg in 2L+ KRAS G12X pancreatic cancer (n=25; AURORAS-1 Phase 1, data cutoff 1 Sep 2026).

Slides by mutation subtype, plus KOL and analyst takes →
#ENA26 #ENA2026
hubs.ly/Q04FYpt80
kolpulse.com ENA 2026 — Top KOL Voices & Trial Buzz ENA 2026, the EORTC-NCI-AACR Symposium · Barcelona, Nov 18–20. KOL slides and early-phase trial buzz: daraxonrasib + chemo in 1L pancreatic cancer, pan-RAS inhibitors, next-generation ADCs and...